What does CENTRE SPECIALITES PHARMACEUTIQUES BENELUX do?

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX is registered with the CBE as active in: Activiteiten van verpakkingsbedrijven. Public Limited, started on 28 April 2008, 1 establishment.

What is the address of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX?

The registered office of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX is located at Chemin de la Reconversion(H-G) 17-19, 7110 La Louvière.

Is CENTRE SPECIALITES PHARMACEUTIQUES BENELUX still active?

Yes. According to the CBE (19 September 2026) CENTRE SPECIALITES PHARMACEUTIQUES BENELUX is active, legal situation “Normale toestand”, started on 28 April 2008.

Is CENTRE SPECIALITES PHARMACEUTIQUES BENELUX registered on Peppol?

Yes, CENTRE SPECIALITES PHARMACEUTIQUES BENELUX is registered on the Peppol network with ID 0208:0897642057.

What is the enterprise number of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX?

The enterprise number of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX is BE0897642057.

Who are the directors of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX?

According to the 2024 annual accounts, the directors of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX are: PATRICK VERKUIJLEN, THOMAS CREUZBERGER.

Is CENTRE SPECIALITES PHARMACEUTIQUES BENELUX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 April 2008; 5 annual accounts filed, latest fiscal year 2024; 2 directors known from the annual account.

How much profit did CENTRE SPECIALITES PHARMACEUTIQUES BENELUX make in 2024?

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX recorded a loss after taxes of € 94,614 in financial year 2024.

What is the revenue of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX?

In its most recent annual accounts (2024), CENTRE SPECIALITES PHARMACEUTIQUES BENELUX reported revenue of € 10,983,480.

How much does an employee at CENTRE SPECIALITES PHARMACEUTIQUES BENELUX earn?

The average wage cost per full-time employee at CENTRE SPECIALITES PHARMACEUTIQUES BENELUX was € 57,000 in 2024: staff costs of € 3.1 million for 54 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CENTRE SPECIALITES PHARMACEUTIQUES BENELUX have?

According to the 2024 annual accounts, CENTRE SPECIALITES PHARMACEUTIQUES BENELUX has 54 full-time equivalents (FTE).

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX (Public Limited)

Q: When was CENTRE SPECIALITES PHARMACEUTIQUES BENELUX founded?

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX was founded on 28 April 2008.

Dossier CENTRE SPECIALITES PHARMACEUTIQUES BENELUX, printed on 19 September 2026 from databakkes.be/en/0897642057/centre-specialites-pharmaceutiques-benelux. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 3 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2023 and 2024.
Figures corrected NBB

Corrected annual account filed for 2024.

Financials

Financial year 2024

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX from La Louvière, company number BE0897642057, closed financial year 2024 with a result of € -94,614 after tax. For that financial year CENTRE SPECIALITES PHARMACEUTIQUES BENELUX recorded revenue of € 11 million and equity of € -1.7 million. Compared with financial year 2023, the result moved from € -762,696 to € -94,614. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on November 3, 2025.

What it is worth Caution

€ -1.7 million

▼ € 94,614 vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -94,614

▲ 88 % less loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 22.4 million

▲ 42% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -2.7 million.

People and assets in 2024

Full-time equivalents

▲ 2.8 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 3.2 million in 2024, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 3.1 million

▲ 8% vs 2023

€ 57,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 90,078

▼ 1% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 4.7 million

▲ 31% vs 2023

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 221 days on average.

Taxes and wages

€ 1.6 million

▲ 11% vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	€ 12,987,616 Revenue 2021: € 12,987,616 First fiscal year in the series	€ 8,445,251 Revenue 2022: € 8,445,251 ▼ 35% vs 2021 (€ 12,987,616) Unfavourable step	€ 9,858,198 Revenue 2023: € 9,858,198 ▲ 17% vs 2022 (€ 8,445,251) Favourable step	€ 10,983,480 Revenue 2024: € 10,983,480 ▲ 11% vs 2023 (€ 9,858,198) Favourable step	▲ 11%
Profit after taxes	€ -375,579 Profit after taxes 2021: € -375,579 First fiscal year in the series	€ -1,648,839 Profit after taxes 2022: € -1,648,839 ▼ € 1.3 million vs 2021 (€ -375,579) Unfavourable step	€ -762,696 Profit after taxes 2023: € -762,696 ▲ € 886,143 vs 2022 (€ -1,648,839) Favourable step	€ -94,614 Profit after taxes 2024: € -94,614 ▲ € 668,082 vs 2023 (€ -762,696) Favourable step	▲ € 668,082
Equity	€ 816,525 Equity 2021: € 816,525 First fiscal year in the series	€ -832,314 Equity 2022: € -832,314 ▼ € 1.6 million vs 2021 (€ 816,525) Unfavourable step	€ -1,595,010 Equity 2023: € -1,595,010 ▼ € 762,696 vs 2022 (€ -832,314) Unfavourable step	€ -1,689,625 Equity 2024: € -1,689,625 ▼ € 94,614 vs 2023 (€ -1,595,010) Unfavourable step	▼ € 94,614
Total debts	€ 16,552,674 Total debts 2021: € 16,552,674 First fiscal year in the series	€ 19,457,556 Total debts 2022: € 19,457,556 ▲ 18% vs 2021 (€ 16,552,674) Unfavourable step	€ 22,544,097 Total debts 2023: € 22,544,097 ▲ 16% vs 2022 (€ 19,457,556) Unfavourable step	€ 30,623,669 Total debts 2024: € 30,623,669 ▲ 36% vs 2023 (€ 22,544,097) Unfavourable step	▲ 36%
Cash	€ 13,905,893 Cash 2021: € 13,905,893 First fiscal year in the series	€ 14,797,509 Cash 2022: € 14,797,509 ▲ 6% vs 2021 (€ 13,905,893) Favourable step	€ 15,739,476 Cash 2023: € 15,739,476 ▲ 6% vs 2022 (€ 14,797,509) Favourable step	€ 22,406,265 Cash 2024: € 22,406,265 ▲ 42% vs 2023 (€ 15,739,476) Favourable step	▲ 42%
Land & buildings	€ 4,699 Land & buildings 2021: € 4,699 First fiscal year in the series	€ 100,961 Land & buildings 2022: € 100,961 ▲ € 96,262 vs 2021 (€ 4,699) Unchanged	€ 203,522 Land & buildings 2023: € 203,522 ▲ 102% vs 2022 (€ 100,961) Unchanged	€ 190,194 Land & buildings 2024: € 190,194 ▼ 7% vs 2023 (€ 203,522) Unchanged	▼ 7%
Retained profit	€ -231,975 Retained profit 2021: € -231,975 First fiscal year in the series	€ -1,880,814 Retained profit 2022: € -1,880,814 ▼ € 1.6 million vs 2021 (€ -231,975) Unfavourable step	€ -2,643,510 Retained profit 2023: € -2,643,510 ▼ € 762,696 vs 2022 (€ -1,880,814) Unfavourable step	€ -2,738,125 Retained profit 2024: € -2,738,125 ▼ € 94,614 vs 2023 (€ -2,643,510) Unfavourable step	▼ € 94,614
Bank debt	€ 580,832 Bank debt 2021: € 580,832 First fiscal year in the series	€ 92,124 Bank debt 2022: € 92,124 ▼ 84% vs 2021 (€ 580,832) Favourable step	€ 40,207 Bank debt 2023: € 40,207 ▼ 56% vs 2022 (€ 92,124) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 40,207) Favourable step	▼ 100%
Balance sheet total	€ 17,369,198 Balance sheet total 2021: € 17,369,198 First fiscal year in the series	€ 18,625,241 Balance sheet total 2022: € 18,625,241 ▲ 7% vs 2021 (€ 17,369,198) Unchanged	€ 20,949,087 Balance sheet total 2023: € 20,949,087 ▲ 12% vs 2022 (€ 18,625,241) Unchanged	€ 28,934,044 Balance sheet total 2024: € 28,934,044 ▲ 38% vs 2023 (€ 20,949,087) Unchanged	▲ 38%
Employees (FTE)	41.4 Employees (FTE) 2021: 41.4 First fiscal year in the series	43.8 Employees (FTE) 2022: 43.8 ▲ 2.4 vs 2021 (41.4) Unchanged	51.2 Employees (FTE) 2023: 51.2 ▲ 7.4 vs 2022 (43.8) Unchanged	54 Employees (FTE) 2024: 54 ▲ 2.8 vs 2023 (51.2) Unchanged	▲ 2.8

Key figures of CENTRE SPECIALITES PHARMACEUTIQUES BENELUX, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to CENTRE SPECIALITES PHARMACEUTIQUES BENELUX?

What happened at CENTRE SPECIALITES PHARMACEUTIQUES BENELUX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Nov 3, 2025 Corrected annual accounts filed for financial year 2024. filed late Source: NBB ↗
2020 PATRICK VERKUIJLEN became a director. NBB
2020 THOMAS CREUZBERGER became a director. NBB
Apr 28, 2008 New establishment in La Louvière. KBO
Apr 28, 2008 Start of the company according to the CBE. KBO

In short

From € 375,579 loss in 2021 to € 94,614 loss in 2024.

Paid € 52,001 in corporate taxes since 2021.

Original PDFs at the National Bank ↗

A new publication or filing at CENTRE SPECIALITES PHARMACEUTIQUES BENELUX? We notify you, reason included.

Follow CENTRE SPECIALITES PHARMACEUTIQUES BENELUX

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

CENTRE SPECIALITES PHARMACEUTIQUES S. Etr. 100%

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX

Behind CENTRE SPECIALITES PHARMACEUTIQUES BENELUX are PATRICK VERKUIJLEN and THOMAS CREUZBERGER. The shares are held by CENTRE SPECIALITES PHARMACEUTIQUES S. Etr. (100%).

See the full network in the app

Directors

According to the 2024 annual accounts

PATRICK VERKUIJLEN

Director

since 2020

THOMAS CREUZBERGER

Director

since 2020

Shareholders

CENTRE SPECIALITES PHARMACEUTIQUES S. Etr.

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Chemin de la Reconversion(H-G) 17-19

7110 La Louvière

2.174.590.342

Chemin de la Reconversion(H-G) 19

7110 La Louvière

Active since 28 April 2008

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0897.642.057

VAT number

BE 0897.642.057

Registered office

Chemin de la Reconversion(H-G) 17-19, 7110 La Louvière

Names & denominations

CENTRE SPECIALITES PHARMACEUTIQUES BENELUX · CSP BENELUX

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 April 2008

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Activiteiten van verpakkingsbedrijven

Opslag

Vervaardiging van andere voedingsmiddelen, neg

Vervaardiging van geneesmiddelen

Groothandel in farmaceutische en medische artikelen

Groothandel in andere voedingsmiddelen, neg

Overige zakelijke dienstverlening, neg

Vervaardiging van farmaceutische grondstoffen

View on CBE Public ↗ Annual accounts (NBB) ↗